UCB S. A.

UCB S. A.

UCB S. A.

Overview
Date Founded

1925

Type of Company

Public

Employees (Worldwide)

8,371

Industries

Pharmaceuticals
Wholesale: Consumer Non-Durables/Sundries
Biotechnology

Company Description

UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.

Contact Data
Trying to get in touch with decision makers at UCB S. A.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer & Chairman of the Executive Committee

Executive Vice President Chief Financial Officer

Executive Vice President & Chief Operating Officer

Executive Vice President & General Counsel

Executive Vice President & Chief Scientific Officer

Executive Vice President & Chief Human Resources Officer

Executive Vice President, Chief Medical Officer & Head of Development & Medical Patent Value Practices

Executive Vice President Immunology Solutions & Head of US

Executive Vice President & Neurology Patient Value Unit Head

Vice Chairman

Board of Directors

Honorary Chairman at Financière de Tubize SA

Chief Executive Officer at Millipore SpA

Vice Chairwoman, Board of Directors at UCB S. A.

Advisor at Ember Technologies, Inc.

President & Chief Executive Officer at X-Vax Technology, Inc.

Director at Financière de Tubize SA

Founder at Health Intelligence Partners LLC

Chief Executive Officer & Chairman of the Executive Committee at UCB S. A.

Co-Founder at OxStem Ltd.

Former Director at UCB S. A.

Paths to UCB S. A.
Potential Connections via
Relationship Science
You
UCB S. A.
Owners & Shareholders
Details Hidden

Eleva Capital actively invests in European equities. They manges three UCITS funds namely: Eleva European Selection, Eleva Euroland Selection and Eleva Absolute Return Europe. Both Eleva European Selection and Eleva Euroland Selection aims to achieve superior long-term risk adjusted return, has medium-term time horizon and invest using bottom-up stock-picking approach. Eleva Absolute Return Europe aims to achieve an absolute return over the medium-term through capital growth. It invests in equity related securities on both a long and short basis and has a differentiated and disciplined bottom-up investment philosophy complemented by a macroeconomic overlay to support sector positioning.

Details Hidden

WMI is an active manager which invests across a range of equity, fixed-income, commodities, alternative and other investment classes following a variety of strategies. Portfolio managers are responsible for both research and investment decisions within their territory, supported by proprietary research which is shared throughout the Wellington group. Their focus is primarily on the UK, Europe, the Middle East and Africa. The firm's proprietary research is the foundation for their investment approach, and is used by specialized teams to invest according to their specific strategies, which combine fundamental research with quantitative valuation techniques. Global industry, regional and macroeconomic experts support both equity and fixed-income investments. Quantitative, technical, style and specialty research teams also contribute to the equity investment processes. Credit, sovereign, quantitative and sector-based analysts support fixed-income investing, working as teams to ensure that bottom-up decisions include relevant top-down factors, and vice versa.

Details Hidden

FOCUS Asset Management GmbH is a private company headquartered in Munich, Germany. The firm provides investment advice. It was founded in 1998. Stefan Ebner is the CEO, in this role since 2012.

Recent Transactions
Details Hidden

UCB S. A. purchases Engage Therapeutics, Inc.

Details Hidden

UCB S. A. purchases Ra Pharmaceuticals, Inc.

Details Hidden

Paragon Partners GmbH purchases Apontis Pharma GmbH & Co. KG from UCB S. A.

Transaction Advisors
Legal Advisor

Advised onUCB S. A. purchases Engage Therapeutics, Inc.

Accountant

Advised onUCB S. A. purchases Solutia, Inc. /Resins Additives & Adhesives Businesses from Solutia, Inc.

Investment Advisor

Advised onUCB S. A. purchases UCB Pharma GmbH

Associate

Advised onLannett Co., Inc. purchases Kremers Urban Pharmaceuticals, Inc. from UCB S. A.

Legal Advisor

Advised onCytec Industries, Inc. purchases UCB SA /Surface Specialty Business from UCB S. A.

Legal Advisor

Advised onLannett Co., Inc. purchases Kremers Urban Pharmaceuticals, Inc. from UCB S. A.

Advisors & Consultants
Legal Advisor

Former Partner at Bondurant Mixson & Elmore LLP

Legal Advisor

Partner at Skadden, Arps, Slate, Meagher & Flom LLP

Clients

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Key Stats and Financials As of 2020
Market Capitalization
$19.9B
Total Enterprise Value
$20B
Earnings Per Share
$4.35
EBITDAMargin
24.89%
Enterprise Value / Sales
3.33x
Enterprise Value EBITDAOperating
13.37x
TEVNet Income
24.31x
Debt TEV
0.15x
Three Year Compounded Annual Growth Rate Of Revenue
5.68%
Revenue
$6B
Net Profit
$822M
EBITDA
$1.49B
Total Debt
$3.08B
Total Equity
$8.16B
Investments
Details Hidden

Dermira, Inc. is a biopharmaceutical company, which engages in the provision of therapies for chronic skin conditions. The company was founded by Thomas G. Wiggans, Eugene Andrew Bauer, Luis C. Peña, and Christopher M. Griffith in 2010 and is headquartered in Menlo Park, CA.

Details Hidden

Ceribell, Inc. engages in the development of diagnosis medical devices. The firm focuses on making electroencephalography (EEG) for diagnosis and treatment of patients at risk for seizures. Its products include Ceribell EEG headband, Ceribell EEG recorder, and spot-checks with brain stethoscope. The company was founded by Jane Chao, Josef Parvizi and Chris Chafe in 2014 and is headquartered in Mountain View, CA.

Details Hidden

Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX.

Suppliers
Nektar Therapeutics Pharmaceuticals | San Francisco, CA

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

Dermira, Inc. Pharmaceuticals | Redwood City, CA

Dermira, Inc. is a biopharmaceutical company, which engages in the provision of therapies for chronic skin conditions. The company was founded by Thomas G. Wiggans, Eugene Andrew Bauer, Luis C. Peña, and Christopher M. Griffith in 2010 and is headquartered in Menlo Park, CA.

Biotie Therapies Oy Pharmaceuticals | Turku, Finland

Biotie Therapies Oy engages in the research, development, and commercialization of pharmaceutical products. The company was founded by Markku Tapani Jalkanen and Sirpa Tuulikki Jalkanen in June 1992 and is headquartered in Helsinki, Finland.

Competitors
AstraZeneca Plc Pharmaceuticals - Cambridge, United Kingdom

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

GlaxoSmithKline Plc Pharmaceuticals - Brentford, Gbr

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

H. Lundbeck A/S Pharmaceuticals - Valby, Denmark

H. Lundbeck A/S engages in the research, development, and market of pharmaceutical products for the treatment of psychiatric and neurological disorders. It operates through the following geographical segments: Europe, the Unites States of America, and International Markets. Its product portfolio targets the following diseases: Alzheimer's, depression, Parkinson's, Schizophrenia, alcohol dependence, anxiety, bipolar disorder, epilepsy, and Huntington's. The company was founded by Hans Lundbeck on August 14, 1915 and is headquartered in Valby, Denmark.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by UCB S. A.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of UCB S. A.'s profile does not indicate a business or promotional relationship of any kind between RelSci and UCB S. A..